Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer

Pancreatic cancer is a devastating disease with a poor prognosis. Novel chemotherapeutics in pancreatic cancer have shown limited success, illustrating the urgent need for new treatments. Lurbinectedin (PM01183; LY-01017) received FDA approval in 2020 for metastatic small cell lung cancer on or afte...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Tej Tummala, Ashley Sanchez Sevilla Uruchurtu, Arielle De La Cruz, Kelsey E. Huntington, Andrew George, Nicholas R. Liguori, Leiqing Zhang, Lanlan Zhou, Abbas E. Abbas, Christopher G. Azzoli, Wafik S. El-Deiry
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2023-10-01
coleção:	Current Oncology
Assuntos:	lurbinectedin (ZEPZELCA™) irinotecan 5-fluorouracil (5-FU) pancreatic cancer combination therapy γH2AX
Acesso em linha:	https://www.mdpi.com/1718-7729/30/11/696
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!